Human SLC7A11&SLC3A2 Full Length Heterodimer Protein (VLP)

Human SLC7A11&SLC3A2 Full Length Heterodimer Protein (VLP) (SLS-H52P4) is expressed from human 293 cells (HEK293). It contains AA Val 2 - Leu 501 (SLC7A11) & Glu 2- Ala 630 (SLC3A2) (Accession # Q9UPY5 (SLC7A11) & P08195 (SLC3A2)).

Product Specifications

Background

Cysteine plays an essential role in cellular redox homoeostasis as a key constituent of the tripeptide glutathione (GSH). A rate limiting step in cellular GSH synthesis is the availability of cysteine. However, circulating cysteine exists in the blood as the oxidised di-peptide cystine, requiring specialised transport systems for its import into the cell. System xc- is a dedicated cystine transporter, importing cystine in exchange for intracellular glutamate. To counteract elevated levels of reactive oxygen species in cancerous cells system xc- is frequently upregulated, making it an attractive target for anticancer therapies.

Specifications

This protein .

Expression Region

Val 2 - Leu 501 (SLC7A11) & Glu 2- Ala 630 (SLC3A2)

Host

HEK 293

Target

SLC7A11 & SLC3A2

Conjugation

Unconjugated

Source

Human

Stability

The product MUST be stored at -70°C or lower upon receipt; -70°C for 12 months under sterile conditions.

Endotoxin

1.0 EU per μg

Bioactivity

Immobilized Human SLC7A11&SLC3A2 Full Length Heterodimer Protein (VLP) (Cat. No. SLS-H52P4) at 5 μg/mL (100 μL/well) can bind Monoclonal Anti-Human SLC7A11 antibody, Human IgG1 with a linear range of 0.01-2.5 μg/mL (QC tested).